Crinetics Pharmaceuticals, Inc. - Common Stock (NQ:CRNX)
Price and Volume
Detailed Quote| Volume | 352,641 |
| Open | 34.32 |
| Bid (Size) | 34.68 (200) |
| Ask (Size) | 34.75 (200) |
| Prev. Close | 34.97 |
| Today's Range | 33.85 - 35.88 |
| 52wk Range | 25.83 - 57.99 |
| Shares Outstanding | 54,026,103 |
| Dividend Yield | N/A |
Top News
More News
Performance
More News
Read More
Crinetics (CRNX) Q1 2026 Earnings Transcript ↗
May 08, 2026
Crinetics (CRNX) Q4 2025 Earnings Call Transcript ↗
February 26, 2026
The market is filled with gapping stocks in Wednesday's session. ↗
January 07, 2026
Frequently Asked Questions
Is Crinetics Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Crinetics Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Crinetics Pharmaceuticals, Inc. - Common Stock trade on?
Crinetics Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Crinetics Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Crinetics Pharmaceuticals, Inc. - Common Stock is CRNX on the Nasdaq Stock Market
What is the current price of Crinetics Pharmaceuticals, Inc. - Common Stock?
The current price of Crinetics Pharmaceuticals, Inc. - Common Stock is 34.68
When was Crinetics Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Crinetics Pharmaceuticals, Inc. - Common Stock was at 06/10/26 03:33 PM ET
What is the market capitalization of Crinetics Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Crinetics Pharmaceuticals, Inc. - Common Stock is 1.87B
How many shares of Crinetics Pharmaceuticals, Inc. - Common Stock are outstanding?
Crinetics Pharmaceuticals, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.